Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Auspex Pharmaceuticals

Biotech & Life Sciences · San Diego, United States · Founded 2001 Unicorn

A biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases

Headcount
<100
Current team size
Unlock exact value

Investors

5 investors on Auspex Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 5 investors entered at this stage
Deerfield
CMEA Capital
Panorama Capital
BioMed Ventures
Thomas McNerney & Partners

Global footprint

Where Auspex Pharmaceuticals has talent and traffic

Workforce by country
🇺🇸 United States · San Diego HQ
Book a demo for the full country breakdown

Patent intelligence

$97M patent portfolio · 44 active families

Estimated portfolio value
$97M
3.7× smaller than top peer Actelion Pharmaceuticals ($361M)
44 active patent families
Where Auspex Pharmaceuticals innovates Medicinal chemistryPharmaceutical drugPharmacologyChemistryPharmaceutical Substances

Where Auspex Pharmaceuticals concentrates vs peers

Each axis is a top-10 topic across Auspex Pharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Auspex Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Auspex Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Auspex Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.